GX Genomics & Biotechnology ETF (GNOM)

$10.80 +0.24 (2.27%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 18,686
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Phone: +1 8884938631
Stocktradesmoon
Stocktradesmoon Jul. 10 at 6:05 AM
$ABCL Biotech ETF Breakouts - $GNOM is the Global X Genomics & Biotechnology ETF. It tracks global companies specializing in gene editing, genomic sequencing, and genetic medicine. - $IBB is the iShares Biotechnology ETF. It is one of the oldest and largest funds tracking standard U.S. biotechnology companies. These charts highlight a strong, highly coordinated technical breakout across the sector. Both funds are pushing past multi-year resistance levels following massive consolidation periods. Imo, $ABCL is best positioned to take advantage of these industry-wide breakouts.
0 · Reply
BreakoutLife
BreakoutLife Jul. 1 at 5:02 PM
$GNOM has already shown meaningful upside momentum, with the ETF up roughly +20% as capital begins to rotate back into genomics and biotech innovation themes. What the market is starting to price in is not just short-term sector strength, but the longer-term optionality around breakthroughs in gene editing, genomics, and therapeutic applications that could reshape entire healthcare segments. In early-stage thematic cycles like this, price often moves ahead of widely recognized “headline moments,” as positioning builds gradually before major narrative catalysts emerge. The key dynamic is whether this remains a short rotation trade or evolves into a sustained multi-phase sector trend driven by real clinical and commercial progress.
0 · Reply
WhaleTracker_
WhaleTracker_ Jun. 22 at 9:03 PM
$GNOM possesses strong structural potential to outperform the S&P 500 over the next few years. While many popular ETFs have rallied hard this year, most are trading near all-time highs (ATHs). In contrast, this genomics and biotech play remains near historical lows (ATLs). Looking forward, this significant valuation reset offers a highly asymmetric risk-reward setup for mean reversion.
0 · Reply
TrendHopeRunner
TrendHopeRunner May. 7 at 11:25 AM
$INO Inovio has patent for HANTA VIRUS $XBI $GNOM $IBB $PBE HTTPS://patents.google.com/patent/US9675684B2/en
1 · Reply
burbs88
burbs88 May. 5 at 12:34 PM
$GNOM
0 · Reply
Stockfinesser20
Stockfinesser20 Apr. 30 at 7:34 PM
$GNOM this has been solid
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 10 at 11:51 AM
Why Is CRSP Stock Falling Pre-Market Today? $CRSP $ARKG $GNOM https://stocktwits.com/news/equity/markets/why-is-crsp-stock-falling-pre-market-today/cZdopfWRI7T
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 10 at 11:23 AM
Why Did BNTX Stock Tumble 17% Pre-Market Today? $BNTX $GNOM $IDNA https://stocktwits.com/news/equity/markets/why-did-bntx-stock-tumble-pre-market-today/cZdoYZmRIey
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 5:29 PM
$GNOM Current Stock Price: $46.98 Contracts to trade: $48.0 GNOM May 15 2026 Call Entry: $3.96 Exit: $7.29 ROI: 84% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
howardlindzon
howardlindzon Feb. 18 at 2:57 PM
$GNOM $IDNA $MRNA
0 · Reply
Latest News on GNOM
Global X Announces Five ETF Reverse Stock Splits

Aug 18, 2025, 5:00 PM EDT - 11 months ago

Global X Announces Five ETF Reverse Stock Splits

CTEC HEAL KROP RNRG

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

Dec 14, 2020, 2:35 PM EST - 6 years ago

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

IBB XBI

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Aug 5, 2020, 12:48 PM EDT - 6 years ago

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

CLOU HERO VGT XLK

Stocktradesmoon
Stocktradesmoon Jul. 10 at 6:05 AM
$ABCL Biotech ETF Breakouts - $GNOM is the Global X Genomics & Biotechnology ETF. It tracks global companies specializing in gene editing, genomic sequencing, and genetic medicine. - $IBB is the iShares Biotechnology ETF. It is one of the oldest and largest funds tracking standard U.S. biotechnology companies. These charts highlight a strong, highly coordinated technical breakout across the sector. Both funds are pushing past multi-year resistance levels following massive consolidation periods. Imo, $ABCL is best positioned to take advantage of these industry-wide breakouts.
0 · Reply
BreakoutLife
BreakoutLife Jul. 1 at 5:02 PM
$GNOM has already shown meaningful upside momentum, with the ETF up roughly +20% as capital begins to rotate back into genomics and biotech innovation themes. What the market is starting to price in is not just short-term sector strength, but the longer-term optionality around breakthroughs in gene editing, genomics, and therapeutic applications that could reshape entire healthcare segments. In early-stage thematic cycles like this, price often moves ahead of widely recognized “headline moments,” as positioning builds gradually before major narrative catalysts emerge. The key dynamic is whether this remains a short rotation trade or evolves into a sustained multi-phase sector trend driven by real clinical and commercial progress.
0 · Reply
WhaleTracker_
WhaleTracker_ Jun. 22 at 9:03 PM
$GNOM possesses strong structural potential to outperform the S&P 500 over the next few years. While many popular ETFs have rallied hard this year, most are trading near all-time highs (ATHs). In contrast, this genomics and biotech play remains near historical lows (ATLs). Looking forward, this significant valuation reset offers a highly asymmetric risk-reward setup for mean reversion.
0 · Reply
TrendHopeRunner
TrendHopeRunner May. 7 at 11:25 AM
$INO Inovio has patent for HANTA VIRUS $XBI $GNOM $IBB $PBE HTTPS://patents.google.com/patent/US9675684B2/en
1 · Reply
burbs88
burbs88 May. 5 at 12:34 PM
$GNOM
0 · Reply
Stockfinesser20
Stockfinesser20 Apr. 30 at 7:34 PM
$GNOM this has been solid
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 10 at 11:51 AM
Why Is CRSP Stock Falling Pre-Market Today? $CRSP $ARKG $GNOM https://stocktwits.com/news/equity/markets/why-is-crsp-stock-falling-pre-market-today/cZdopfWRI7T
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 10 at 11:23 AM
Why Did BNTX Stock Tumble 17% Pre-Market Today? $BNTX $GNOM $IDNA https://stocktwits.com/news/equity/markets/why-did-bntx-stock-tumble-pre-market-today/cZdoYZmRIey
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 5:29 PM
$GNOM Current Stock Price: $46.98 Contracts to trade: $48.0 GNOM May 15 2026 Call Entry: $3.96 Exit: $7.29 ROI: 84% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
howardlindzon
howardlindzon Feb. 18 at 2:57 PM
$GNOM $IDNA $MRNA
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 18 at 2:57 PM
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review $MRNA $IDNA $GNOM https://stocktwits.com/news/equity/markets/moderna-stock-fda-accepts-revised-flu-vaccine-application-for-review/cZR0MwoR4v1
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 5:56 PM
$GNOM Current Stock Price: $48.22 Contracts to trade: $45 GNOM Jan 16 2026 Call Entry: $0.70 Exit: $1.28 ROI: 83% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CashFlowAnalyst
CashFlowAnalyst Dec. 25 at 3:30 PM
$GNOM Investors are recalibrating expectations as the balance shifts from vision to execution. Execution gaps should narrow meaningfully over coming quarters. A series of confirmed wins might reduce the required risk premium. Execution precision will determine whether this evolves or stalls.
0 · Reply
Renato17
Renato17 Dec. 23 at 7:55 PM
$SBIO $GNOM $QQQ $SPY https://www.biomedwire.com/ resource
0 · Reply
Reversal_Levels
Reversal_Levels Oct. 15 at 12:37 PM
6/ * Chart of the day is $GNOM. (selected for demo purposes) * Dark clouds + sea ice + "fish" gave the perfect entry point in April. * This is a good example how green mountain can go away and come back, as you see in Aug and Sep. * Current gold on the mountain + lava can always be a peak. But it is higher than the peak in July, so there is no divergence. This rally may have further to go.
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:32 AM
$BMRN $GNOM $BBH $IBB Biomarin calls indicate max pain can shift to $60 with a 15% upside. Check out max pain...
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:30 AM
$BMRN $BBH $IBB $GNOM Biomarin darkpool activity and algos bought and price held. Check my posts below.
0 · Reply
Thelonius_Stonk
Thelonius_Stonk Sep. 7 at 10:50 AM
$GNOM looks better than idna and arkg since april lows. don't expect to get through this resistance immediately
1 · Reply
603stockgoat
603stockgoat Aug. 25 at 8:02 PM
$GNOM this or $ARKG ?
1 · Reply